Urogen Pharma Ltd
NASDAQ:URGN
Urogen Pharma Ltd
NASDAQ:URGN
Price:
17.62
USD
-5.22%
Market Closed
Market Cap:
$824.8m
Balance Sheet
Balance Sheet Decomposition
Urogen Pharma Ltd
Urogen Pharma Ltd
Balance Sheet Decomposition is not available for
Urogen Pharma Ltd
Urogen Pharma Ltd
Balance Sheet
Urogen Pharma Ltd
Urogen Pharma Ltd
Currency: USD
| Dec-2013 | Dec-2014 | Dec-2015 | Dec-2016 | Dec-2017 | Dec-2018 | Dec-2019 | Dec-2020 | Dec-2021 | Dec-2022 | Dec-2023 | Dec-2024 | Dec-2025 | ||
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Assets | ||||||||||||||
| Cash & Cash Equivalents |
3
|
4
|
18
|
21
|
37
|
101
|
50
|
53
|
44
|
55
|
95
|
172
|
111
|
|
| Cash Equivalents |
3
|
4
|
18
|
21
|
37
|
101
|
50
|
53
|
44
|
55
|
95
|
172
|
111
|
|
| Short-Term Investments |
0
|
0
|
0
|
0
|
36
|
0
|
97
|
49
|
45
|
45
|
42
|
65
|
10
|
|
| Total Receivables |
0
|
0
|
0
|
0
|
0
|
0
|
0
|
7
|
12
|
13
|
15
|
20
|
33
|
|
| Accounts Receivables |
0
|
0
|
0
|
0
|
0
|
0
|
0
|
7
|
12
|
13
|
15
|
20
|
33
|
|
| Other Receivables |
0
|
0
|
0
|
0
|
0
|
0
|
0
|
0
|
0
|
0
|
0
|
0
|
0
|
|
| Inventory |
0
|
0
|
0
|
0
|
0
|
0
|
0
|
2
|
5
|
4
|
6
|
9
|
16
|
|
| Other Current Assets |
0
|
0
|
1
|
1
|
1
|
1
|
2
|
5
|
9
|
12
|
11
|
10
|
16
|
|
| Total Current Assets |
3
|
4
|
19
|
22
|
75
|
102
|
149
|
116
|
114
|
129
|
169
|
276
|
186
|
|
| PP&E Net |
0
|
0
|
0
|
1
|
1
|
1
|
5
|
4
|
3
|
4
|
2
|
4
|
9
|
|
| PP&E Gross |
0
|
0
|
0
|
1
|
1
|
1
|
5
|
4
|
3
|
4
|
2
|
4
|
9
|
|
| Accumulated Depreciation |
0
|
0
|
0
|
0
|
1
|
1
|
1
|
1
|
2
|
3
|
4
|
4
|
5
|
|
| Long-Term Investments |
0
|
0
|
0
|
0
|
0
|
0
|
49
|
2
|
1
|
0
|
5
|
5
|
0
|
|
| Other Long-Term Assets |
0
|
0
|
0
|
0
|
0
|
0
|
1
|
0
|
2
|
3
|
2
|
1
|
5
|
|
| Total Assets |
3
N/A
|
4
+38%
|
19
+341%
|
23
+19%
|
76
+227%
|
104
+37%
|
202
+95%
|
122
-40%
|
120
-2%
|
136
+13%
|
178
+31%
|
286
+60%
|
200
-30%
|
|
| Liabilities | ||||||||||||||
| Accounts Payable |
0
|
1
|
2
|
2
|
3
|
4
|
5
|
3
|
6
|
6
|
7
|
11
|
12
|
|
| Accrued Liabilities |
0
|
0
|
1
|
1
|
4
|
9
|
15
|
18
|
14
|
16
|
22
|
28
|
30
|
|
| Short-Term Debt |
0
|
0
|
0
|
0
|
0
|
0
|
0
|
0
|
0
|
0
|
0
|
0
|
0
|
|
| Current Portion of Long-Term Debt |
0
|
0
|
0
|
0
|
0
|
0
|
0
|
0
|
0
|
0
|
0
|
1
|
1
|
|
| Other Current Liabilities |
0
|
0
|
0
|
1
|
1
|
0
|
0
|
1
|
2
|
2
|
3
|
6
|
3
|
|
| Total Current Liabilities |
1
|
1
|
2
|
3
|
7
|
14
|
20
|
21
|
22
|
24
|
31
|
46
|
46
|
|
| Long-Term Debt |
0
|
0
|
1
|
4
|
0
|
0
|
0
|
0
|
0
|
98
|
99
|
123
|
126
|
|
| Other Liabilities |
0
|
0
|
0
|
0
|
0
|
0
|
3
|
4
|
89
|
104
|
114
|
125
|
134
|
|
| Total Liabilities |
1
N/A
|
1
+140%
|
3
+158%
|
7
+116%
|
7
+4%
|
14
+93%
|
22
+64%
|
26
+16%
|
111
+333%
|
225
+102%
|
244
+8%
|
295
+21%
|
306
+4%
|
|
| Equity | ||||||||||||||
| Common Stock |
0
|
0
|
0
|
0
|
0
|
0
|
0
|
0
|
0
|
0
|
0
|
0
|
0
|
|
| Retained Earnings |
8
|
13
|
25
|
27
|
47
|
123
|
228
|
357
|
467
|
577
|
679
|
806
|
960
|
|
| Additional Paid In Capital |
11
|
16
|
42
|
44
|
116
|
213
|
408
|
453
|
476
|
488
|
614
|
797
|
854
|
|
| Other Equity |
0
|
0
|
0
|
0
|
0
|
0
|
0
|
0
|
0
|
0
|
0
|
0
|
0
|
|
| Total Equity |
3
N/A
|
3
+19%
|
16
+409%
|
16
N/A
|
69
+320%
|
90
+32%
|
180
+100%
|
96
-47%
|
8
-91%
|
89
N/A
|
65
+27%
|
9
+87%
|
105
-1 098%
|
|
| Total Liabilities & Equity |
3
N/A
|
4
+38%
|
19
+341%
|
23
+19%
|
76
+227%
|
104
+37%
|
202
+95%
|
122
-40%
|
120
-2%
|
136
+13%
|
178
+31%
|
286
+60%
|
200
-30%
|
|
| Shares Outstanding | ||||||||||||||
| Common Shares Outstanding |
11
|
11
|
11
|
11
|
14
|
16
|
21
|
22
|
23
|
23
|
32
|
42
|
48
|
|
Switch to:
Switch to:
See Also
Discover More
